Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index; 20 of the 29 sources its claims cite were checked for support.

Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial

Open access

Abstract

Background: While some evidence suggests that l-arginine may improve sexual function and alleviate depression, it has not been investigated in women with depression to assess both its effects on the depression and sexual function concurrently. Methods: Patients who had received a diagnosis of major depressive disorder, as determined by predetermined inclusion and exclusion criteria, were enrolled in this triple-blind clinical trial. Patients were divided into two groups: group A, received L-arginine 1 gram twice daily, and group B, received a placebo for four weeks. They were evaluated at baseline, after four and eight weeks with the Hamilton Depression Rating Scale (HDRS), and Rosen’s questionnaire or Female Sexual Function Index (FSFI). Results: A decrease in the severity of depression was observed in all patients, which was determined due to Hamilton’s questionnaire (P-value < 0.001). During the time in group A, FSFI increased. Based on the FSFI questionnaire, they had improvement in some domains, including the lubrication index and orgasm index, which significantly changed in the eighth week compared to the baseline (P-value < 0.05). However, these two indicators did not change statistically significantly compared to the placebo group. Conclusion: L-arginine supplementation can improve sexual function, particularly lubrication and orgasm, and mood in women with depression, with minimal side effects observed. Additional research is necessary to validate these results by examining the effects of higher dosages, extended durations, and larger populations of depressed patients. Trial registration: Iranian Registry of Clinical Trial: IRCT20100127003210N26. © The Author(s) 2024.

Overview

CoChat Summary

TL;DR

This triple-blind randomized trial in women with major depressive disorder found that adding l-arginine 1 g twice daily for 4 weeks improved some sexual function subdomains within the treatment group, especially lubrication and orgasm, but not significantly versus placebo. Depression severity decreased over time in both groups, and the added l-arginine did not produce a statistically significant between-group benefit.

Key findings

  • The study enrolled 32 women with major depressive disorder: 16 received l-arginine and 16 received placebo.
  • In the l-arginine group, FSFI lubrication and orgasm indices improved significantly over time, with reported p-values of 0.032 and 0.023, respectively; however, these changes were not statistically significant compared with placebo.
  • Depression severity measured by HDRS decreased significantly over time in both groups (P_time < 0.001), but the intervention had no significant between-group effect on HDRS changes (P_time*group < 0.001 is reported for interaction over time, yet the paper also states no significant difference between groups at measured time points).
  • In multivariable GEE analysis, there was no significant association between treatment group and changes in HDRS, FSFI, or FSFI subgroups; the average FSFI difference for l-arginine versus placebo was β = 0.37, 95% CI -4.99 to 5.74, P = 0.891.

Methods

  • Triple-blind, randomized clinical trial conducted from August 2022 to August 2023 at the psychiatric departments of Ayatollah Taleghani Hospital, Tehran, Iran.
  • Participants were women aged 18–60 years with major depressive disorder by DSM-5 criteria; all were on standard antidepressant treatment (sertraline or escitalopram), then randomized to l-arginine 1 g twice daily or placebo for 4 weeks.
  • Outcomes were assessed at baseline, week 4, and week 8 using Hamilton Depression Rating Scale (HDRS) and FSFI/Rosen’s questionnaire; analysis used intention-to-treat, t-test/Mann-Whitney, chi-square/Fisher’s exact tests, and generalized estimating equations (GEE).

Limitations

  • The paper states that the Iranian pharmaceutical market lacked high-dose l-arginine products, so the study used the minimum effective dose from prior studies rather than higher doses.
  • The authors report recruitment challenges due to cultural considerations in Iran and note that the 8-week timeframe likely discouraged participation in a longer treatment period.
  • Evident from the text: the sample was small (n = 32) and the intervention period was short (4 weeks of l-arginine/placebo), which limits precision and the ability to detect modest effects.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12888-024-05781-5

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Flowchart of the recruitment of volunteers and allocation to each group of intervention
Fig. 1 Flowchart of the recruitment of volunteers and allocation to each group of interventionCC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 3 Not valid · 5 Not checked · 26 Own results and interpretations

18 more claims

Create a free account to see all 46 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 13
  • It may state two separate claims as one. 11
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 47 references

Research works printed but not linked: 1

  1. Menafra D, de Angelis C, Garifalos F, Mazzella M, Galdiero G, Piscopo M, et al. Long-term high- dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double- blind, randomized, placebo-controlled clinical trial. J Endocrinol Investig. 2022;45(5):941–61. · DOI · Paper page

Metadata

Authors
Torkaman, P., Meybodi, A. M., Kheradmand, A., Eiliaei, S., & Ardakani, M. T.
Affiliations
  • Shahid Beheshti University (IR)
  • Taleghani General Hospital (IR)
Corresponding author
Ardakani, Maria Tavakoli
Venue
BMC Psychiatry
Published
2024-05-14
Volume
24
Issue
1
Pages
358-358
ISSN
1471-244X (ISSN-L)
OpenAlex
W4396894568
Cited by
1
References
47
Citations by year
2026: 1
FWCI
0.29
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Shahid Beheshti University of Medical Sciences
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Sexuality, Behavior, and Technology
Keywords
L-arginine, major depressive disorder, female sexual function, women with depression, sexual lubrication, orgasm, depression severity, dietary supplementation
MeSH terms
Adult, Arginine, Major Depressive Disorder, Double-Blind Method, Female, Humans, Middle Aged, Sexual Behavior, Sexual Dysfunction, Physiological, Treatment Outcome, Sexual Dysfunctions, Psychological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial. https://app.cochat.ai/papers/10.1186/s12888-024-05781-5
The paper
Torkaman, P., Meybodi, A. M., Kheradmand, A., Eiliaei, S., & Ardakani, M. T. (2024). Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial. BMC Psychiatry. https://doi.org/10.1186/s12888-024-05781-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.